Cargando…

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects

AIM: To determine the effective dose of glibenclamide by quantifying the dose–response relationship in South African type 2 diabetic patients. PATIENTS AND METHODS: A total of 24 type 2 diabetic patients participated in a glibenclamide dose-escalation study during which glibenclamide, glucose, and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rambiritch, Virendra, Naidoo, Poobalan, Pillai, Goonaseelan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5044993/ https://www.ncbi.nlm.nih.gov/pubmed/27713650 http://dx.doi.org/10.2147/CPAA.S102674

Ejemplares similares

Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
por: Rambiritch, Virendra, et al.
Publicado: (2016)

Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study
por: Rambiritch, Virendra, et al.
Publicado: (2014)

Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study
por: Naidoo, Poobalan, et al.
Publicado: (2016)

Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014)

Non-referral of potential organ donors in South Africa: insights, challenges and ethical dilemmas
por: Naidoo, Poobalan, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats
por: Prashanth, S., et al.
Publicado: (2011)

Pharmacokinetic interaction of curcumin and glibenclamide in diabetic rats
por: Devi, P. R. Sakunthala, et al.
Publicado: (2015)

Management of adult patients with type 1 diabetes mellitus in Africa: A post-hoc cohort analysis of 12 African countries participating in the International Diabetes Management Practices Study (Wave 7)
por: Mbanya, Jean Claude, et al.
Publicado: (2020)

Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis
por: Jacobson, Barry, et al.
Publicado: (2019)

Real-world evidence and product development: Opportunities, challenges and risk mitigation
por: Naidoo, Poobalan, et al.
Publicado: (2021)

Formulation of Glibenclamide proniosomes for oral administration: Pharmaceutical and pharmacodynamics evaluation
por: Alshora, Doaa, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide
por: Irvine, Hannah J., et al.
Publicado: (2022)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
por: Bi, Youwei, et al.
Publicado: (2018)

Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats
por: Bin Jardan, Yousef A., et al.
Publicado: (2021)

Health Care Resource Utilization in Adults Living With Type 1 Diabetes Mellitus in the South African Public Health Sector: Protocol for a 1-Year Retrospective Analysis With a 5-, 10-, and 25-Year Projection
por: Bhana, Sindeep, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
por: Morello, Candis M
Publicado: (2011)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

Glibenclamide Prevents Diabetes in NOD Mice
por: Lamprianou, Smaragda, et al.
Publicado: (2016)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus
por: Sun, Lin, et al.
Publicado: (2011)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
por: Jadhav, Satyawan B., et al.
Publicado: (2023)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
por: Vajda, Eric G., et al.
Publicado: (2016)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome
por: Yang, Shuying, et al.
Publicado: (2016)

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
por: Kim, Choon Ok, et al.
Publicado: (2020)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6lldeldbs9qk2ov5mdppfemn4e